Ciencias de la Salud

URI permanente para esta comunidadhttp://repositorio.uta.edu.ec/handle/123456789/813

Examinar

Resultados de la búsqueda

Mostrando 1 - 1 de 1
  • Item type:Ítem,
    CANNABIDIOL COMO TERAPIA ALTERNATIVA EN EL TRATAMIENTO DE EPILEPSIA REFRACTARIA EN PACIENTES PEDIÁTRICOS
    (2025-10-15)
    Calucho Aguilar, Diego Leonardo
    ;
    Paredes Lascano, Patricia Lorena
    ;
    Universidad Técnica de Ambato / Facultad de Ciencias de Salud / Carrera de Medicina
    Introduction: Refractory epilepsy, present in 30% of pediatric patients, represents a significant clinical challenge. Cannabidiol (CBD) has been proposed as a promising therapeutic alternative. Objective: To analyze the available evidence on the efficacy and safety of CBD in the treatment of refractory epilepsy in pediatric patients through a systematic literature review. Methods: A systematic review was conducted following PRISMA guidelines. PubMed/MEDLINE and Scopus databases were searched to identify studies published between January 2020 and September 2024. Randomized con-trolled trials and observational studies evaluating the efficacy and/or safety of CBD in pediatric pa-tients with refractory epilepsy were included. Results: Nine studies meeting the selection criteria were included. The findings indicate a significant reduction in seizure frequency in 56–78% of patients treated with CBD, with some studies reporting seizure frequency reductions exceeding 50%. Efficacy was sustained over follow-up periods of up to 156 weeks. CBD demonstrated a favorable safety pro-file, with adverse events generally mild to moderate, including drowsiness, decreased appetite, and diarrhea. Several studies reported improvements in patients’ quality of life and cognitive functioning, assessed using standardized tools. Conclusions: Current evidence suggests that CBD may be an effective and safe therapeutic option for the treatment of refractory epilepsy in pediatric patients. Further studies are needed to establish optimal dosing protocols andevaluate long-term effects.